Exhibit 5. Logistic Regression Model Predicting Noncompliance for Part D Recipients1 with Select Cardiovascular Agent Use2, Age 65 and Over, 2007.
| Odds Ratio Point Estimate 3 by Therapeu Class | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Characteristic | Anti-anginals 8 | Antihyper-tensives | Anti-arrhythmics 10 | Antihyper-lipidemics 11 | Betatic Blockers 12 | Calcium Blockers 13 | Cardio-tonics 14 | Diuretics 15 | |
| Region | |||||||||
| Midwest | 1.139 | 1.003 * | 1.046 | 1.034 | 1.000 * | 0.967 | 1.020 * | 0.964 | |
| South | 1.261 | 1.263 | 1.279 | 1.304 | 1.276 | 1.219 | 1.207 | 1.239 | |
| West | 1.086 | 1.025 | 1.157 | 0.944 | 1.028 | 1.047 | 1.024 * | 0.909 | |
| Other | 2.138 | 2.585 | 1.509 | 2.870 | 2.155 | 2.470 | 2.336 | 2.096 | |
| Northeast | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | |
| Gender | |||||||||
| Female | 0.758 | 0.806 | 0.755 | 0.938 | 0.731 | 0.804 | 0.791 | 0.873 | |
| Male | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | |
| Age | |||||||||
| 85+ | 0.730 | 0.713 | 0.882 | 0.764 | 0.727 | 0.685 | 0.900 | 0.812 | |
| 75-84 | 0.866 | 0.850 | 0.940 | 0.897 | 0.857 | 0.834 | 0.955 | 0.910 | |
| 65-74 | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | |
| Racial/Ethnic | |||||||||
| Origin | |||||||||
| Black | 1.442 | 1.681 | 1.457 | 1.742 | 1.732 | 1.949 | 1.708 | 1.498 | |
| Hispanic | 1.068 | 1.405 | 1.053 * | 1.506 | 1.267 | 1.486 | 1.053 | 1.109 | |
| Other | 0.793 | 0.905 | 0.786 | 0.911 | 0.868 | 0.958 | 0.888 | 0.805 | |
| White | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | |
| Disease Burden 4 | |||||||||
| Highest | 1.273 | 1.287 | 1.464 | 1.025 | 1.395 | 1.281 | 1.543 | 1.440 | |
| Medium High | 1.166 | 1.080 | 1.229 | 1.017 | 1.116 | 1.076 | 1.147 | 1.136 | |
| Medium Low | 1.226 | 1.162 | 1.354 | 1.039 | 1.222 | 1.147 | 1.286 | 1.282 | |
| Lowest | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | |
| Dual Status | |||||||||
| Dual 5 | 0.957 | 0.745 | 0.664 | 0.670 | 0.700 | 0.755 | 0.724 | 0.767 | |
| Non Dual 5 | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | |
| PDP Status | |||||||||
| MAPD 5 | 0.984 | 1.060 | 0.976 | 1.078 | 1.028 | 1.057 | 0.957 | 0.954 | |
| PDP5 | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | |
| Relative OOP | |||||||||
| Non-Class Costs 6 | |||||||||
| Highest | 0.788 | 0.611 | 0.789 | 0.665 | 0.641 | 0.518 | 0.690 | 0.774 | |
| Medium High | 0.895 | 0.921 | 0.946 | 0.983 | 0.884 | 0.843 | 0.853 | 0.911 | |
| Medium Low | 0.832 | 0.777 | 0.876 | 0.886 | 0.767 | 0.693 | 0.745 | 0.840 | |
| Lowest | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | |
| Relative OOP | |||||||||
| Daily Class Costs 7 | |||||||||
| Highest | 1.530 | 1.917 | 1.333 | 1.623 | 1.687 | 1.929 | 1.669 | 1.530 | |
| Medium High | 1.094 | 1.352 | 1.242 | 1.156 | 1.224 | 1.101 | 1.076 | 1.101 | |
| Medium Low | 1.316 | 1.323 | 1.290 | 1.585 | 1.522 | 1.433 | 1.387 | 1.538 | |
| Lowest | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | 1.0-- | |
A Part D recipient is a Medicare beneficiary enrolled for 12 months in a Medicare Part D program and who received at least one medication. Non-compliance based on within-class percentage (e.g., percentage of non-compliant females to all female recipients).
Medications identified using the Medi-Span database. Medi-Span is a product of Wolters Kluwer Health. See http://www.wkhealth.com for details.
Higher ratio (>1) = greater odds for noncompliance. Asterisk denotes p > 0.05.
Disease burden based on hierarchical condition category risk scores acquired from the Centers for Medicare & Medicaid Services. Derivation based on quartiles.
Enrollees enrolled for the entire twelve months as this classification for calendar year 2007.
Relative Out-of-Pocket (OOP) Non-Class costs. Derivation based on quartiles. Quartile assigment made by (a)assigning the enrollee into one of the two groups of duals or non duals and (b) comparing the enrollee's OOP costs for all medications outside (i.e., external to) the class under study to other enrollees in the same assigned group.
Relative Out-of-Pocket (OOP) Daily Class costs. Derivation based on quartiles. Quartile assigment made by (a)assigning the enrollee into one of the two groups of duals or non duals and (b) comparing the enrollee's daily OOP costs for medications within the class under study to other enrollees in the same assigned group.
Max-rescaled R2 = 0.0220.
Max-rescaled R2 = 0.0335.
Max-rescaled R2 = 0.0202.
Max-rescaled R2 = 0.0348.
Max-rescaled R2 = 0.0353.
Max-rescaled R2 = 0.0410.
Max-rescaled R2 = 0.0253.
Max-rescaled R2 = 0.0254.